Mark Talamonti to CA-19-9 Antigen
This is a "connection" page, showing publications Mark Talamonti has written about CA-19-9 Antigen.
Connection Strength
0.240
-
CA 19-9 nonproduction is associated with poor survival after resection of pancreatic adenocarcinoma. Am J Clin Oncol. 2014 Dec; 37(6):550-4.
Score: 0.124
-
Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011 Jun 01; 80(2):476-82.
Score: 0.097
-
Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008 Feb 20; 26(6):942-7.
Score: 0.019